From Marketbeat

Bausch Health Companies was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research report. Jefferies Financial Group also upgraded shares of the company and lifted their price target.

BHC last opened at $7.75, with a 50-day moving average of $7.13. The stock’s market cap is $2.83 billion, with a PE ratio of -2.94, and a debt-to-equity ratio of 74.20. BHC has a twelve month range between $5.57 and $10.23.

Bausch Health Companies posted quarterly earnings data. They reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.11. Bausch Health Companies had a negative net margin of 11.27% and a positive return on equity of 1,124.72%.

Institutional investors and hedge funds boosted their stakes in Bausch Health Companies. About 74.56% of the stock is currently owned by hedge funds and other institutional investors.

Bausch Health Companies operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health.

Before you consider investing in Bausch Health Companies, top-rated analysts believe there are five other stocks that are better buys. Click the link below to view the five stocks recommended by top-rated analysts. Get MarketBeat’s guide to investing in 5G and which 5G stocks show the most promise.

Read more: Bausch Health Companies (NYSE:BHC) Upgraded at StockNews.com